NICE - Endorsed Technology Appraisals 2015/2016

It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.

Technology Appraisals Endorsement Process

The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland.  The new arrangements are detailed in following circulars, which is effective from 18th December 2013;

For information, details of the previous arrangement can be found on the following circular;


The following technology appraisals have been endorsed during 2015/16. Information on technology appraisals endorsed in previous years can be found on the homepage.

Fully Endorsed 

March 2016

February 2016

‘Note this guidance has been partially replaced by TA864 - Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted, endorsed by the DoH in February 2023.’

January 2016

December 2015

November 2015

October 2015

September 2015

August 2015

June 2015

May 2015

Endorsed with caveats


Not Endorsed as Applicable to Northern Ireland 


Back to top